Epigenetic alterations contribute significantly to the development and progression of
prostate cancer, the most prevalent malignant tumor in males of Western industrialized …

Prostate cancer is the most common malignancy and the second leading cause of cancer
death among men in the United States. There are three well-established risk factors for …

Promoter hypermethylation is associated with the loss of expression of tumor-suppressor
genes in cancer. Currently, several genome-wide technologies are available and have been …

The prostate gland is the most common site of cancer and the second leading cause of
cancer death in American men. Recent emerging molecular biological technologies help us …

Prostate cancer (PCa) is the most prevalent cancer, a significant contributor to morbidity and
a leading cause of cancer-related death in men in Western industrialized countries. In …

Aberrant DNA methylation is one of the hallmarks of carcinogenesis and has been
recognized in cancer cells for more than 20 years. The role of DNA methylation in malignant …

BACKGROUND DNA hypermethylation has emerged as a novel molecular biomarker for the
evaluation of prostate cancer diagnosis and prognosis. Defining the specific gene …

Background: Prostate cancer (PCa) harbors a myriad of genomic and epigenetic defects.
Cytosine methylation of CpG-rich promoter DNA is an important mechanism of epigenetic …

Prostate cancer is the most common malignancy of the urogenital tract. Although
controversial, prostate‐specific antigen (PSA) testing is widely used for screening and follow …

BACKGROUND Alterations of DNA methylation have been reported in many human
cancers. In prostatic carcinoma, hypermethylation of the GST P gene promoter and an …